Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

Daniel A. Goldstein; Qiushi Chen; David H. Howard; Joseph Lipscomb; Turgay Ayer; Bassel El-Rayes; Christopher R. Flowers

首页> 外文期刊>Gastrointestinal Cancer Research >Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

【24h】

Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

机译：贝伐单抗（Bev）在转移性结直肠癌（mCRC）一线和二线治疗中的成本效益分析（CEA）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Gastrointestinal Cancer Research》 |2014年第1期|共8页
作者
Daniel A. Goldstein; Qiushi Chen; David H. Howard; Joseph Lipscomb; Turgay Ayer; Bassel El-Rayes; Christopher R. Flowers;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. 6074 Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study [J] . J.Bennouna, F.Husseini, J.P.Delord, European Journal of Cancer Supplements . 2009,第2期

机译：6074贝伐单抗（bev）联合化学疗法作为转移性结直肠癌（mCRC）的二线治疗：BEVACOLOR II期研究的结果
2. 6074 Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study [J] . J.Bennouna, F.Husseini, J.P.Delord, European Journal of Cancer Supplements . 2009,第2期

机译：6074贝伐单抗（bev）联合化学疗法作为转移性结直肠癌（mCRC）的二线治疗：BEVACOLOR II期研究的结果
3. THE COST EFFECTIVENESS ANALYSIS OF CAPDX VERSUS FOLFOX-4 REGIMENS WITH OR WITHOUT BEVACIZUMAB IN THE FIRST LINE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN HONG KONG [J] . Lee V. W., Cheng F., Wan K. P., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：香港转移性结直肠癌（MCRC）第一线管理中具有或不带Bevacizumab的CAPDX与Folfox-4方案的成本效益分析
4. Single Cell Genomic Profiling of Circulating Tumor Cells (CTCs) from Metastatic Colorectal Cancer (mCRC) Identify Tumor Heterogeneity and Rare Somatic Driver Alterations [C] . Stephanie Greene, Angel Rodriguez, Jerry Lee, International Molecular Medicine Tri-Conference. . 2016

机译：转移结直肠癌（MCRC）的循环肿瘤细胞（CTC）的单细胞基因组分析识别肿瘤异质性和稀有躯体驾驶员改变
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC) [O] . Daniel A. Goldstein, Qiushi Chen, David H. Howard, 2014

机译：贝伐单抗（Bev）在转移性结直肠癌（mCRC）一线和二线治疗中的成本效益分析（CEA）
7. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC) : results of the AIO KRK 0207 phase III\ua0study [O] . Hegewisch-Becker, Susanna, Arnold, Dirk, Lerchenmufcller, Christian, 2014

机译：标准方法联合使用FP，奥沙利铂（Ox）和Bev作为转移性结直肠癌（mCRC）患者的一线治疗后，采用氟嘧啶（FP）加贝伐单抗（Bev），单独或不进行治疗的维持策略AIO KRK 0207第III阶段\ ua0研究

Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

著录项

相似文献

相关主题

期刊订阅